Genedrive completes assay design for Covid-19 test kit

Thu, 22nd Oct 2020

Diagnostics company Genedrive said it had completed the assay design of its COVID-19 testing and was now generating 'very promising' analytical data aligned to market requirements. The company's SARS-CoV-2 POC Kit was being designed to detect the Covid-19 virus in saliva without the need to extract viral RNA. 'This expanded the potential use areas of the product and importantly, allows for rapid testing to be performed while a patient was present,' the company said. At 8:32am: (LON:GDR) Genedrive Plc share price was -4.5p at 108.5p Story provided by StockMarketWire.com

FTSE 100 Latest
Value6,735.71
Change-66.25